TrialOncotarget2013

Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.

Julia Y Wagner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.